Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.781

Related search